This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Second this, and I would have said it less carefully.
This follows post #29 rather than contradicting it.
Two questions I would want answered before drawing anything from the pharmacy supply data above: how were the cases selected, and what happened to the ones that dropped out.
Nothing in this subcategory is medical or legal advice, and prescribers reading here consistently say so themselves.
Post #33 and I disagree about the size of the effect, not about the direction.
Small methodological point on pharmacy supply: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.
The most useful contribution is a link to the current official page with the date you accessed it. That survives; a paraphrase does not.
Caveat: everything above assumes the paperwork is what it says it is.
Having read the whole pharmacy supply thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a nearby one instead.
Narrowing post #37, because the general version has more than one answer.
Availability through a private route and availability through the public system are separate questions and both change independently.
An honest declaration on pharmacy supply: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.
Private prescribing is legal and widespread, including through remote consultation. Pharmacies must satisfy themselves that a prescription is clinically appropriate. Expect to be asked for measurements and history.
This is the version I would want a new member to read first.
Answering the question post #40 raises rather than the one it answers.
Waiting times are the most variable and least generalisable thing reported here, and they are worth posting anyway with a region and a date.
That is where I would start, not where I would stop.
Post #42 is the version of this I will quote in future. One addition.
My understanding of pharmacy supply is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
Where the compound is supplied with a device, the device and the compound have separate availability positions and the device is more often the constraint.
Useful. I had the fact and not the reason, which turns out to be the important half.
Post #44 put the caveat in the right place and I want to underline it.
Clinical guidance published for prescribers is public and answers most eligibility questions here more precisely than the discussion does.
I would treat the number as indicative rather than as a measurement.
Filing a mild objection to the consensus on pharmacy supply. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.
Clear enough that I do not think I have a follow-up, which is unusual.
Supply and shortage resilience: both UK and Ireland sourced primarily from European suppliers until recent disruptions. Domestic availability and pricing changed.
That is the honest state of it as of this week.
Agreed on pharmacy supply, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.
Pharmacy practice varies between pharmacies and is not deducible from the regulatory position. Two people can honestly report opposite experiences.
That much is documented. The rest is how I have interpreted it.
Taking pharmacy supply seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.
Post #55 is the version of this I will quote in future. One addition.
Cross-border movement between the two jurisdictions is not the same as domestic movement within either, and the rules are published rather than inferred.
The step people skip is the one I have spelled out.
Summarising the pharmacy supply thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.
Pharmacy supply is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.